Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination

Vaccine

Volumn 32, Issue 1, 2013, Pages 111-118

  Smits, Kaatje ^a   Pottier, Gaelle ^a   Smet, Julie ^a   Dirix, Violette ^a   Vermeulen, Françoise ^b   De Schutter, Iris ^c   Carollo, Maria ^d   Locht, Camille ^e,f,g   Ausiello, Clara Maria ^d   Mascart, Françoise ^a,b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e INSERM U1019   (France)

^f CNRS   (France)

^g UNIV LILLE   (France)

Author keywords

Acellular pertussis vaccine; Children; Immune response; Memory T cell; Whole cell pertussis vaccine

Indexed keywords

ANTIGEN; BP ANTIGEN; COMBIVAX; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; GAMMA INTERFERON; HEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MEMORY CELL; MEMORY T LYMPHOCYTE; NORMAL HUMAN; PERTUSSIS; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE;

ACELLULAR PERTUSSIS; ACELLULAR PERTUSSIS VACCINE; AP; BORDETELLA PERTUSSIS; BP; CHILDREN; FHA; FILAMENTOUS HEMAGGLUTININ; IMMUNE RESPONSE; MEMORY T CELL; PBMC; PERIPHERAL BLOOD MONONUCLEAR CELLS; PERTUSSIS TOXIN; PT; SEB; STAPHYLOCOCCUS ENTEROTOXIN B; WHOLE-CELL PERTUSSIS; WHOLE-CELL PERTUSSIS VACCINE; WP;

ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; CYTOKINES; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; PERTUSSIS VACCINE; PHENOTYPE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; VACCINATION; WHOOPING COUGH;

EID: 84891905046     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.056     Document Type: Article

References (46)

1. Chiappini E., Stival A., Galli L., de Martino M. Pertussis re-emergence in the post-vaccination era. BMC Infect Dis 2013, 13:151.
2. Liko J., Robison S.G., Cieslak P.R. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med 2013, 368:581-582.
3. Clark T.A., Messonnier N.E., Hadler S.C. Pertussis control: time for something new?. Trends Microbiol 2012, 20:211-213.
4. Zepp F., Heininger U., Mertsola J., Bernatowska E., Guiso N., Roord J., et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011, 11:557-570.
5. Cherry J.D. Epidemic pertussis in 2012 - the resurgence of a vaccine-preventable disease. N Engl J Med 2012, 367:785-787.
6. Cherry J.D. Why do pertussis vaccines fail?. Pediatrics 2012, 129:968-970.
7. Wiedermann B.L. What's wrong with acellular pertussis vaccines?. Clin Ther 2013, 35:115-118.
8. Libster R., Edwards K.M. Re-emergence of pertussis: what are the solutions?. Expert Rev Vaccines 2012, 11:1331-1346.
9. Klein N.P., Bartlett J., Fireman B., Rowhani-Rahbar A., Baxter R. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 2013, 131:e1716-e1722.
10. Tartof S.Y., Lewis M., Kenyon C., White K., Osborn A., Liko J., et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013, 131:e1047-e1052.
11. Misegades L.K., Winter K., Harriman K., Talarico J., Messonnier N.E., Clark T.A., et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. J Am Med Assoc 2012, 308:2126-2132.
12. Higgs R., Higgins S.C., Ross P.J., Mills K.H.G. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol 2012, 5:485-500.
13. Mills K.H. Immunity to Bordetella pertussis. Microbes Infect Inst Pasteur 2001, 3:655-677.
14. De Gouw D., Diavatopoulos D.A., Bootsma H.J., Hermans P.W.M., Mooi F.R. Pertussis: a matter of immune modulation. FEMS Microbiol Rev 2011, 35:441-474.
15. Mills K.H., Barnard A., Watkins J., Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 1993, 61:399-410.
16. Mills K.H., Ryan M., Ryan E., Mahon B.P. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998, 66:594-602.
17. Leef M., Elkins K.L., Barbic J., Shahin R.D. Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J Exp Med 2000, 191:1841-1852.
18. Watanabe M., Komatsu E., Sato T., Nagai M. Evaluation of efficacy in terms of antibody levels and cell-mediated immunity of acellular pertussis vaccines in a murine model of respiratory infection. FEMS Immunol Med Microbiol 2002, 33:219-225.
19. Warfel J.M., Merkel T.J. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol 2013, 6:787-796.
20. Ross P.J., Sutton C.E., Higgins S., Allen A.C., Walsh K., Misiak A., et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog 2013, 9:e1003264.
21. McGuirk P., McCann C., Mills K.H.G., Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 2002, 195:221-231.
22. Mascart F., Verscheure V., Malfroot A., Hainaut M., Piérard D., Temerman S., et al. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol (Baltimore, MD) 2003, 1950(170):1504-1509.
23. Mascart F., Hainaut M., Peltier A., Verscheure V., Levy J., Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 2007, 25:391-398.
24. Ausiello C.M., Urbani F., la Sala A., Lande R., Cassone A. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun 1997, 65:2168-2174.
25. Ausiello C.M., Lande R., Urbani F., la Sala A., Stefanelli P., Salmaso S., et al. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect Immun 1999, 67:4064-4071.
26. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8:247-258.
27. Carollo M., Palazzo R., Bianco M., Smits K., Mascart F., Ausiello C.M. Antigen-specific responses assessment for the evaluation of Bordetella pertussis T cell immunity in humans. Vaccine 2012, 30:1667-1674.
28. Nasso M., Fedele G., Spensieri F., Palazzo R., Costantino P., Rappuoli R., et al. Genetically detoxified pertussis toxin induces Th1/Th17 immune response through MAPKs and IL-10-dependent mechanisms. J Immunol (Baltimore, MD) 2009, 1950(183):1892-1899.
29. Roederer M., Nozzi J.L., Nason M.X., SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. Cytom A: J Int Soc Anal Cytol 2011, 79:167-174.
30. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334:349-355.
31. Granström M., Olinder-Nielsen A.M., Holmblad P., Mark A., Hanngren K. Specific immunoglobulin for treatment of whooping cough. Lancet 1991, 338:1230-1233.
32. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16:1907-1916.
33. Taranger J., Trollfors B., Lagergård T., Sundh V., Bryla D.A., Schneerson R., et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 2000, 181:1010-1013.
34. Sato H., Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect Immun 1984, 46:415-421.
35. Hendrikx L.H., Oztürk K., de Rond L.G.H., Veenhoven R.H., Sanders E.A.M., Berbers G.A.M., et al. Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins. Vaccine 2011, 29:1431-1437.
36. Morel S., Denoël P., Godfroid F., Cortvrindt C., Vanderheyde N., Poolman J. Induction of Bordetella pertussis-specific immune memory by DTPa vaccines. Vaccine 2011, 29:3449-3455.
37. Dirix V., Verscheure V., Vermeulen F., De Schutter I., Goetghebuer T., Locht C., et al. Both CD4+ and CD8+ lymphocytes participate in the IFN-γ response to filamentous hemagglutinin from Bordetella pertussis in infants, children, and adults. Clin Dev Immunol 2012, 2012:7958-7959.
38. Sheridan S.L., Ware R.S., Grimwood K., Lambert S.B. Number and order of whole cell pertussis vaccines in infancy and disease protection. J Am Med Assoc 2012, 308:454-456.
39. Witt M.A., Arias L., Katz P.H., Truong E.T., Witt D.J. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis Off Publ Infect Dis Soc Am 2013, 56:1248-1254.
40. Hendrikx L.H., Felderhof M.K., Oztürk K., de Rond L.G.H., van Houten M.A., Sanders E.A.M., et al. Enhanced memory B-cell immune responses after a second acellular pertussis booster vaccination in children 9 years of age. Vaccine 2011, 30:51-58.
41. Hendrikx L.H., de Rond L.G.H., Oztürk K., Veenhoven R.H., Sanders E.A.M., Berbers G.A.M., et al. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age. Vaccine 2011, 29:5725-5730.
42. Schure R.-M., Hendrikx L.H., de Rond L.G.H., Oztürk K., Sanders E.A.M., Berbers G.A.M., et al. Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination. Clin Vaccine Immunol 2013, 20:1388-1395.
43. De Greeff S.C., Teunis P., de Melker H.E., Mooi F.R., Notermans D.W., Elvers B., et al. Two-component cluster analysis of a large serodiagnostic database for specificity of increases of IgG antibodies against pertussis toxin in paired serum samples and of absolute values in single serum samples. Clin Vaccine Immunol 2012, 19:1452-1456.
44. De Greeff S.C., de Melker H.E., van Gageldonk P.G.M., Schellekens J.F.P., van der Klis F.R.M., Mollema L., et al. Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PloS ONE 2010, 5:e14183.
45. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005, 18:326-382.
46. Sharma S.K., Pichichero M.E. Functional deficits of pertussis-specific CD4+ T cells in infants compared to adults following DTaP vaccination. Clin Exp Immunol 2012, 169:281-291.